Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Free Cash Flow (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Free Cash Flow for 5 consecutive years, with -$21.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 18.16% year-over-year to -$21.7 million, compared with a TTM value of -$82.5 million through Dec 2025, down 2.18%, and an annual FY2025 reading of -$82.5 million, down 2.02% over the prior year.
  • Free Cash Flow was -$21.7 million for Q4 2025 at Aligos Therapeutics, up from -$24.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$13.6 million in Q2 2023 and bottomed at -$37.8 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$22.0 million, with a median of -$21.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 55.38% in 2022, then tumbled 43.16% in 2024.
  • Year by year, Free Cash Flow stood at -$37.8 million in 2021, then surged by 55.38% to -$16.9 million in 2022, then crashed by 34.28% to -$22.7 million in 2023, then grew by 18.78% to -$18.4 million in 2024, then fell by 18.16% to -$21.7 million in 2025.
  • Business Quant data shows Free Cash Flow for ALGS at -$21.7 million in Q4 2025, -$24.3 million in Q3 2025, and -$15.5 million in Q2 2025.